Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. - Wikidata - awgldk - TriplyDB

Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.

Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.

http://www.wikidata.org/entity/Q33336860

about

Very important pharmacogene summary: thiopurine S-methyltransferase Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing Idiopathic Inflammatory Myopathies: Clinical Approach and Management A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm Idiopathic inflammatory myopathies The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity Drug methylation in cancer therapy: lessons from the TPMT polymorphism Pharmacogenetics in inflammatory bowel disease Pharmacogenomic discovery using cell-based models Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia Thiopurine methyltransferase genotyping in Palestinian childhood acute lymphoblastic leukemia patients.Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases Idiopathic inflammatory myopathies.Thiopurine methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells after thioguanine exposure.Atopic and non-atopic eczema.Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.Pharmacogenomics: marshalling the human genome to individualise drug therapy Pharmacogenomic considerations in drug delivery.Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance.A review and assessment of potential sources of ethnic differences in drug responsiveness.Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.PharmGED: Pharmacogenetic Effect Database.Inherited genetic variation in childhood acute lymphoblastic leukemia.Moving towards individualized medicine with pharmacogenomics.Thiopurine S-methyltransferase genetic polymorphism in the Thai population Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review.Frequency of thiopurine S-methyltransferase mutant alleles in indigenous and admixed Guatemalan patients with acute lymphoblastic leukemia.Pharmacogenomics of adverse effects of anti-leukemic agents in children.Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.Clinical implication of thiopurine methyltransferase polymorphism in children with acute lymphoblastic leukemia: A preliminary Egyptian study.Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group The role of pharmacogenetics in cancer therapeutics.

P2860

Q24601748-0B5046B1-88BE-405B-A4F3-71BD3165E44F Q24632749-5EA7E3FF-4A84-4DF9-9583-A12A57EC76CE Q26744705-27C15365-73D9-4B3B-8C7C-968211DADC03 Q26866379-F344E86E-7F19-4115-80F7-01C9847BFE0B Q27025125-1A303060-B929-48B3-B181-5093184156EA Q28080256-2B571CD8-B51E-4ECE-9ED1-7F56812258CE Q28082746-7CB2C780-D35A-4A6B-896D-520304A4A708 Q28087637-D4CA2EBF-4B80-454A-BD86-62C821910F4C Q28115755-F43CEDCF-E510-43E2-A0A5-FC9AB35B37AF Q28212325-1C4B1FDD-0646-481B-8EEF-A21B3F62D616 Q28246002-EC6E6025-AA62-434F-8719-71A13A23727B Q28392982-372A6DF6-E962-4490-AB5E-61D39A6F7F84 Q28943308-1ACC02FA-5AB5-4F69-B795-BCFE52050927 Q31150912-7DC15B44-71F6-46DF-8DD3-009C15D63316 Q33576773-EB9BC04A-BBFC-4F7A-86FE-FC1E6A11E671 Q33603164-BF9A6F60-AD92-4B3C-BCD4-04941C7B2953 Q33674158-B068AF13-C325-4E39-A4E5-325C256C0851 Q33838866-1BBE86A2-88B9-4F26-B098-BFA894AB376A Q33924451-73069974-0D3D-4CC1-8BAD-5E6F6329BA73 Q34117269-2D383F97-6D6E-41B1-8E92-D7A7E1DE753B Q34441292-8AD9E998-2156-4883-B3CB-DA34FC46D4CE Q34459885-0FCB1801-759B-415A-9F36-6323DA5A5DA6 Q34609157-48CBD4B8-480C-4CDF-B08D-FB637FFA7AD0 Q35090217-A32109BA-E894-463D-9B9B-A9D437CF0D2C Q35164676-9D45719E-594F-4FD6-89FF-3CA0A683BDC9 Q35206306-3521114F-E9B3-4190-89D1-3771B415E0FF Q35217493-F5236E14-18B9-47CF-AD13-F37BCD406196 Q35539576-CC074D9D-04C4-4FF3-9DCF-A88BDCD692B8 Q35567962-B848CCFC-607A-401B-9506-9280A4A29800 Q35784497-87DE8B73-169C-4AFB-852E-3799CBFE2D7E Q35784527-44532CC4-BC58-4EB8-9775-6E3CA01C977B Q35826222-BD046B9D-8079-4FAC-B6CE-FD052DCD1A56 Q35848092-16835F76-B09B-4CBC-8012-BE5FF1C86FAD Q35971977-BCE2E2A1-24FE-402B-90EC-DF3BF26FB4C0 Q35984724-2C7DBA22-D40B-4090-B05F-E4F536FCCAE6 Q36191097-D09C835E-AC1F-4E88-9F28-016CA15E76CA Q36402208-D0763139-7749-4251-85F4-938D77F82F02 Q36458023-38C30290-EBD2-4CE7-91D4-10889C2967EA Q36491833-5A8A83A9-31BB-472A-AF16-3A74FBC9E3DD Q36536674-EB04129E-A799-4F38-AE35-B4EF9E6EE7DE

P2860

Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.

http://www.wikidata.org/entity/Q33336860

description

2001 nî lūn-bûn

@nan

2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Preponderance of thiopurine S- ...... ercaptopurine or azathioprine.

@ast

Preponderance of thiopurine S- ...... ercaptopurine or azathioprine.

@en

Preponderance of thiopurine S- ...... ercaptopurine or azathioprine.

@nl

type

label

Preponderance of thiopurine S- ...... ercaptopurine or azathioprine.

@ast

Preponderance of thiopurine S- ...... ercaptopurine or azathioprine.

@en

Preponderance of thiopurine S- ...... ercaptopurine or azathioprine.

@nl

prefLabel

Preponderance of thiopurine S- ...... ercaptopurine or azathioprine.

@ast

Preponderance of thiopurine S- ...... ercaptopurine or azathioprine.

@en

Preponderance of thiopurine S- ...... ercaptopurine or azathioprine.

@nl

P1433

Q33336860-032CC639-8E2C-4BD2-A30B-96DF1F59594F

P1476

Q33336860-0AC9836B-910F-443D-B4B0-D6B0983B01DA

P2093

Q33336860-0595F425-8867-49EF-9CA8-F3892197B334

Q33336860-08952D9A-C79E-4DC3-A8E6-1F59C74C0788

Q33336860-0BAB7E6E-CBC0-41C2-A0E9-045559CC80F0

Q33336860-18E0C910-2506-4C7B-9126-53197A145009

Q33336860-569AD62B-A6B0-4A54-81AA-E15FFB2F1A1E

Q33336860-63E7E7C7-C672-4906-9975-474CC7D6B80D

Q33336860-72893FBC-833B-4D7F-B930-F477C42FE3BA

Q33336860-8392F168-76B7-4B92-A216-D48C69C19DCD

Q33336860-8BD1DAD5-CE6D-46A0-BE7C-7BFCDF295478

Q33336860-8ECFBD89-1949-4939-94A1-0C4319B9144E

P304

Q33336860-39438028-0126-43F6-A8CF-7E3BCBDC00E7

P31

Q33336860-A578B768-135C-4116-AA3A-936DF34E27AA

P356

Q33336860-A5A58D39-CF66-4E2D-B33B-F0C5BC2385B5

P407

Q33336860-BCF7E5FB-FEB4-4BB6-907D-E532C39B097F

P433

Q33336860-3A238C0E-ED58-4D25-862B-DD7FABEBB90B

P478

Q33336860-7BE5B94E-9E01-41DB-9B01-CEF7716EC5D5

P577

Q33336860-8D949BB7-A084-4684-B605-5E249B14D6EC

P698

Q33336860-AB6D6285-16A1-4B6A-93E9-0A5656140F7A

P921

Q33336860-67604B27-ED81-4B19-BD54-520E4D25B089

Q33336860-C0703816-42D6-42BC-B148-8174EE4A42B5

P356

JCO.2001.19.8.2293

P1433

Journal of Clinical Oncology

P1476

Preponderance of thiopurine S- ...... ercaptopurine or azathioprine.

@en

P2093

C Steuber

http://www.w3.org/2001/XMLSchema#string

D Kalwinsky

http://www.w3.org/2001/XMLSchema#string

D Schiff

http://www.w3.org/2001/XMLSchema#string

E Y Krynetski

http://www.w3.org/2001/XMLSchema#string

F Keller

http://www.w3.org/2001/XMLSchema#string

F Tucci

http://www.w3.org/2001/XMLSchema#string

J Margolin

http://www.w3.org/2001/XMLSchema#string

J Murray

http://www.w3.org/2001/XMLSchema#string

J Quinn

http://www.w3.org/2001/XMLSchema#string

K Ritchey

http://www.w3.org/2001/XMLSchema#string

P304

2293-2301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2001.19.8.2293

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2001-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11304783

http://www.w3.org/2001/XMLSchema#string

P921

thiopurine S-methyltransferase deficiency